Nephros (NEPH) Stock: Buy, Sell, or Hold?
NEPH - Nephros Inc.
$3.67
0.00 (0.00%)
▲
5d:
-13.24%
30d:
-12.93%
90d:
+3.38%
HOLD
MODERATE Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When NEPH Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: NEPH shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: NEPH shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$9.91
Based on 13.8% avg growth
INTRINSIC VALUE TODAY
$6.15
40.3% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: NEPH is currently trading at $3.67, which is considered oversold relative to its 30-day fair value range of $3.96 to $4.43. From a valuation perspective, the stock is trading at a discount (Forward PE: 17.5) compared to its historical average (27.6). Remarkably, the market is currently pricing in an annual earnings decline of 14.1% over the next few years. This pessimistic expectation contrasts with the company's recent 450.0% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, NEPH is in a strong uptrend. Immediate support is located at $3.50, while resistance sits at $4.40.
Market Sentiment: NEPH scores 39/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $6.25 (+70.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, NEPH is in a strong uptrend. Immediate support is located at $3.50, while resistance sits at $4.40.
Market Sentiment: NEPH scores 39/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $6.25 (+70.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$3.96 -
$4.43
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (39/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 70.3% below Wall St target ($6.25)
- CAUTION: 5-day price weakness (-13.2%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$3.96 -
$4.43
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$3.50
Resistance Level
$4.40
Current Trend
Strong Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
17.48
Wall Street Target
$6.25
(+70.3%)
Revenue Growth (YoY)
36.2%
Earnings Growth (YoY)
450.0%
Profit Margin
8.4%
Valuation Discount vs History
-14.1% cheaper
PE vs Historical
17.5 vs 27.6
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-14.1%
(market-implied from PE analysis)
1-Year Target
$3.30
(-10%)
2-Year Target
$2.97
(-19%)
3-Year Target
$2.68
(-27%)
3-Yr Target (if PE normalizes)
(PE: 17→28)
$4.23
(+15%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.4, Growth: 23.5%)
$8.08
(+120%)
Base:
(SPY PE: 17.5, Growth: 23.5%)
$6.92
(+89%)
Bear:
(PE: 14.9, Growth: 23.5%)
$5.88
(+60%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (23x PE), but valuation improves significantly next year (17x PE) as earnings recover.
Trailing PE: 22.94 | Current EPS (TTM): $0.16
Bull Case
$5.30
(+44%)
Analyst growth 31.2%, PE expands to 25.2
Base Case
$4.82
(+31%)
Market implied 31.2%, PE stable at 22.9
Bear Case
$2.50
(-32%)
Severe decline -20.0%, PE contracts to 19.5
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 17.5 to 27.6
Stabilization Target:
$5.80
(+57.9%)
PE Expansion Potential:
+57.9%
Share & Embed Analysis
Last updated: October 03, 2026 3:00 AM ET
Data refreshes hourly during market hours. Next update: 4:00 AM
Data refreshes hourly during market hours. Next update: 4:00 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NEPH showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Instruments & Supplies Stocks
Top-rated stocks in Medical Instruments & Supplies by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALC
Alcon AG |
STRONG BUY
27 analysts |
$84 | 53 HOLD |
|
ISRG
Intuitive Surgical Inc |
BUY
33 analysts |
$476 | 35 SELL |
|
COO
The Cooper Companies, Inc |
BUY
19 analysts |
$66 | 67 BUY |
|
RMD
ResMed Inc |
BUY
19 analysts |
$250 | 61 BUY |
|
ALGN
Align Technology Inc |
BUY
18 analysts |
$206 | 65 BUY |
